Prenatal exposure to organomercury, thimerosal, persistently impairs the serotonergic and dopaminergic systems in the rat brain: Implications for association with developmental disorders

Brain and Development

Volumn 35, Issue 3, 2013, Pages 261-264

  Ida Eto, Michiru ^a   Oyabu, Akiko ^a   Ohkawara, Takeshi ^a   Tashiro, Yasura ^a   Narita, Naoko ^b   Narita, Masaaki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BUNKYO UNIVERSITY   (Japan)

Author keywords

Developmental disorders; Dopamine; Embryonic exposure; Rat; Serotonin; Thimerosal

Indexed keywords

ORGANOMERCURY COMPOUND; SEROTONIN; THIOMERSAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; EMBRYO; FEMALE; HIPPOCAMPUS; NEUROTOXICITY; NEWBORN DEATH; NONHUMAN; POSTNATAL DEVELOPMENT; PRENATAL EXPOSURE; RAT; SEROTONINERGIC SYSTEM;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DEVELOPMENTAL DISABILITIES; DOPAMINE; FEMALE; HIPPOCAMPUS; MALE; NEOSTRIATUM; ORGANOMERCURY COMPOUNDS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESERVATIVES, PHARMACEUTICAL; RATS; RATS, WISTAR; SEROTONIN; THIMEROSAL;

EID: 84873748942     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2012.05.004     Document Type: Article

References (20)

1. Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol 2001, 21:1-5.
2. Clarkson T.W., Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 2006, 36:609-662.
3. Dórea J.G. Integrating experimental (in vitro and in vivo) neurotoxicity studies of low-dose thimerosal relevant to vaccines. Neurochem Res 2011, 36:927-938.
4. Ball L.K., Ball R., Pratt R.D. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001, 107:1147-1154.
5. Young H.A., Geier D.A., Geier M.R. Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110-118.
6. Verstraeten T., Davis R.L., DeStefano F., Lieu T.A., Rhodes P.H., Black S.B., et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003, 112:1039-1048.
7. Olczak M., Duszczyk M., Mierzejewski P., Majewska M.D. Neonatal administration of a vaccine preservative, thimerosal, produces lasting impairment of nociception and apparent activation of opioid system in rats. Brain Res 2009, 1301:143-151.
8. Olczak M., Duszczyk M., Mierzejewski P., Bobrowicz T., Majewska M.D. Neonatal administration of thimerosal causes persistent changes in mu opioid receptors in the rat brain. Neurochem Res 2010, 35:1840-1847.
9. Olczak M., Duszczyk M., Mierzejewski P., Meyza K., Majewska M.D. Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of thimerosal in rats. Behav Brain Res 2011, 223:107-118.
10. Lawton M., Iqbal M., Kontovraki M., Lloyd Mills C., Hargreaves A.J. Reduced tubulin tyrosination as an early marker of mercury toxicity in differentiating N2a cells. Toxicol In Vitro 2007, 21:1258-1261.
11. Ida-Eto M., Oyabu A., Ohkawara T., Tashiro Y., Narita N., Narita M. Embryonic exposure to thimerosal, an organomercury compound, causes abnormal early development of serotonergic neurons. Neurosci Lett 2011, 505:61-64.
12. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
13. Miyazaki K., Narita N., Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 2005, 23:287-297.
14. Narita M., Oyabu A., Imura Y., Kamada N., Yokoyama T., Tano K., et al. Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. Neurosci Res 2010, 66:2-6.
15. Thompson W.W., Price C., Goodson B., Shay D.K., Benson P., Hinrichsen V.L., et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007, 357:1281-1292.
16. Price C.S., Thompson W.W., Goodson B., Weintraub E.S., Croen L.A., Hinrichsen V.L., et al. Prenatal and infant exposure to Thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics 2010, 126:656-664.
17. Strömland K., Nordin V., Miller M., Akerström B., Gillberg C. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 1994, 36:351-356.
18. Williams G., King J., Cunningham M., Stephan M., Kerr B., Hersh J.H. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001, 43:202-206.
19. Faro L.R., Rodrigues K.J., Santana M.B., Vidal L., Alfonso M., Durán R. Comparative effects of organic and inorganic mercury on in vivo dopamine release in freely moving rats. Braz J Med Biol Res 2007, 40:1361-1365.
20. Ye W., Shimamura K., Rubenstein J.L.R., Hynes M.A., Rosenthal A. FGF and Shh signals control dopaminergic and serotonergic cell fate in anterior neural plate. Cell 1998, 93:755-766.